When a society/ organisation/ publisher partner with open evidence, what is the benefit they get
Searching the Web
Open Evidence partner society organisation publisher benefits
Reading Web Page
benefits for society publisher partner OpenEvidence
Here is a clear breakdown of the benefits a society, organisation, or publisher gets when partnering with OpenEvidence:
Benefits of Partnering with OpenEvidence
1. Expanded Reach & Impact for Their Content
Partner content (journals, systematic reviews, guidelines) is surfaced directly to physicians at the point of care - the exact moment a clinical decision is being made. For example, Cochrane's CEO noted the partnership ensures AI-powered tools are "based on the best possible evidence," extending the real-world reach of their publications far beyond traditional readership. As the Wiley-OpenEvidence announcement put it: content now reaches physicians "where those decisions are getting made."
2. Licensing Revenue
Publishers license their content portfolio to OpenEvidence in exchange for fees. This creates a new, recurring revenue stream from existing content assets - separate from traditional journal subscriptions.
3. Brand Visibility & Credibility in AI
As AI becomes central to clinical workflows, being a named source within the world's most-used medical AI platform (OpenEvidence claims the largest physician user base globally) keeps the partner's brand front-and-center with the medical community.
4. Bridging the "17-Year Gap"
Research shows it takes an average of 17 years for new evidence to reach clinical practice. Partnering with OpenEvidence dramatically accelerates this - meaning a society's or publisher's research actually influences patient care much faster. This is a core mission benefit for societies that exist to advance clinical knowledge.
5. Future Collaboration Opportunities
The Wiley deal explicitly names future collaboration areas, including:
- Deepening society relationships
- Expanding networks and connections
- Global expansion opportunities
- New healthcare and life sciences use cases (e.g., CME, guideline tools)
6. Alignment with AI-Era Strategy
For publishers and societies, being inside a leading AI platform signals forward-looking relevance. The JAMA Network deal was framed as ensuring high-quality, peer-reviewed evidence remains the foundation of AI-generated clinical answers - rather than being displaced by lower-quality sources.
7. Support for Mission Goals (for Societies Specifically)
Medical societies exist to advance their specialty and improve patient outcomes. Partnering with OpenEvidence directly serves that mission: their guidelines and research reach practicing physicians instantly, reducing information overload and supporting better decisions.
In short: partners get licensing revenue, massively amplified content reach, brand presence in AI-driven clinical workflows, and a faster pipeline from research to bedside - all while ensuring their trusted content, rather than lower-quality data, underpins AI-generated medical answers.
Create a document summarizing partnership benefits for publisher prospecting
Reading File
Reading File
Many of these societies have different kind of proprietary data, so they have to have members who can access this by being a member And now, because of AI, the usage might have decreased. What about that? Can someone access the paywall data from open evidence?
Searching the Web
OpenEvidence paywalled journal content access model - do users need subscription
Searching the Web
OpenEvidence publisher licensing model journal access membership societies AI
This is a sharp concern, and the research gives us a clear picture. Here's the honest breakdown:
Can Users Access Paywalled Content Through OpenEvidence?
The short answer: Yes - but indirectly, and by design.
When a publisher/society licenses their content to OpenEvidence, physicians can get AI-synthesized answers drawn from that paywalled content - without holding a personal subscription to the journal. OpenEvidence itself is free to any US physician with an NPI number (National Provider Identifier). So technically, a doctor who never paid for a NEJM or Cochrane subscription can now get answers grounded in that content.
The "Disintermediation" Risk You're Pointing At
This is a real tension in the industry. The concern is:
- A society journal charges members $500/year partly because members need access to the content
- Physicians can now get the clinical answers from that content via OpenEvidence for free
- Result: membership/subscription value proposition weakens, and society revenue could erode
This mirrors the broader "AI disintermediation" pattern seen across media and publishing.
How Publishers Are Framing It (and Why They're Still Signing)
The Sequoia Capital interview with OpenEvidence founder Daniel Nadler reveals a key insight: OpenEvidence sends millions of physician visits back to journal pages as cited sources. The model is:
AI answer + citation link → physician clicks through to the original article → journal gets traffic and engagement
So publishers are betting that OpenEvidence acts as a discovery and referral engine, not a substitute. The logic: a physician who would never have found or read a niche Cochrane review now encounters it, clicks the citation, and the journal gets a verified, engaged reader.
But the Risk Is Real - Especially for Societies
For medical societies specifically, the calculus is more complicated than for commercial publishers:
| Factor | Commercial Publisher | Medical Society |
|---|---|---|
| Revenue model | Mostly licensing/subscriptions | Membership fees + journal access bundled |
| Content exclusivity | Strong (large back-catalogue) | Moderate (guidelines, standards of care) |
| AI cannibalization risk | Lower (already diversifying revenue) | Higher (membership access is the core value prop) |
| Upside from AI partnership | Licensing fees + reach | Mission impact + some licensing revenue |
Societies like the American Diabetes Association, American College of Cardiology, and AAO-HNSF have already partnered with OpenEvidence - so they've evidently decided the reach and mission benefit outweighs the membership access risk. But this is a legitimate concern they'd need to address in how they structure the deal (e.g. linking full-text access to members only, while OpenEvidence only surfaces synthesized answers with citations).
The Key Structural Question for Prospecting
When approaching a society, the honest framing should address this directly:
- OpenEvidence surfaces synthesized answers with citations, not full article text
- Full-text access still requires clicking through to the journal (which can remain paywalled/member-only)
- The partnership can be structured so that full text is only unlocked for members, while non-members see the AI answer + a prompt to join/subscribe for full access
- This could actually increase membership conversions by exposing non-members to the value of the society's content at the moment they need it most
This "freemium gateway" framing - where OpenEvidence is the top-of-funnel and membership is the unlock for full text - would be a strong angle in publisher/society prospecting conversations.
This is a shared conversation. Sign in to Orris to start your own chat.